A five-item tool using spirometry and basic clinical data may predict recurrent tuberculosis with moderate accuracy, helping ...

Lower-income countries, including South Africa, gain unprecedented access to lenacapavir, a revolutionary HIV prevention drug ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

Federal Minister for National Health Services, Regulations and Coordination, Syed Mustafa Kamal on Wednesday emphasized that ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.